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Summary: This clinical practice guideline presents recommendations for systemic antibacterial 
prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation patients. The 
recommendations were developed by an international panel based on the results of a systematic review of 
114 randomized trials. 
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ABSTRACT 
Introduction: Bacteremia and other invasive bacterial infections are common among children with cancer 
receiving intensive chemotherapy and in pediatric recipients of hematopoietic stem cell transplantation 
(HSCT).  Systemic antibacterial prophylaxis is one approach that can be used to reduce the risk of these 
infections. Our purpose was to develop a clinical practice guideline (CPG) for systemic antibacterial 
prophylaxis administration in pediatric cancer and HSCT patients. 
Methods: An international and multi-disciplinary panel was convened with representation from pediatric 
hematology/oncology and HSCT, pediatric infectious diseases (including antibiotic stewardship), nursing, 
pharmacy, a patient advocate and a CPG methodologist. The panel used the Grading of Recommendations 
Assessment, Development, and Evaluation (GRADE) approach to generate recommendations based on 
the results of a systematic review of the literature.  
Results: The systematic review identified 114 eligible randomized trials of antibiotic prophylaxis. The 
panel made a weak recommendation for systemic antibacterial prophylaxis for children receiving 
intensive chemotherapy for acute myeloid leukemia and relapsed acute lymphoblastic leukemia (ALL). 
Weak recommendations against the routine use of systemic antibacterial prophylaxis were made for 
children undergoing induction chemotherapy for ALL, autologous HSCT and allogeneic HSCT. A strong 
recommendation against its routine use was made for children whose therapy is not expected to result in 
prolonged severe neutropenia. If used, prophylaxis with levofloxacin was recommended during severe 
neutropenia. 
Conclusions: We present a CPG for systemic antibacterial prophylaxis administration in pediatric cancer 
and HSCT patients. Future research should evaluate the long-term effectiveness and adverse effects of 
prophylaxis. 
Keywords: practice guideline; bacterial infection; prevention; pediatric, oncology, hematopoietic stem 
cell transplantation 
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Introduction 
Bacteremia and other invasive bacterial infections are common among children with cancer 
receiving intensive chemotherapy and pediatric recipients of hematopoietic stem cell transplantation 
(HSCT).[1-3] Systemic antibacterial prophylaxis is one approach that can be used to reduce the risk of 
these infections. Decision making regarding routine utilization of antibacterial prophylaxis involves 
weighing measures of efficacy against potential negative consequences. Measures of efficacy of 
prophylaxis include reductions in fever, bacteremia, sepsis, infection-related mortality and overall 
mortality. Potential negative consequences of prophylaxis include Clostridioides difficile infection, 
invasive fungal disease, drug toxicities and antibiotic resistance.[4-6]    
While decision making regarding antibacterial prophylaxis will be informed by local bacterial 
resistance patterns and jurisdictional drug availability, development of a clinical practice guideline (CPG) 
may promote more standardized practice. A CPG was developed by the American Society of Clinical 
Oncology and the Infectious Diseases Society of America for patients with cancer but the target audience 
was restricted to adults.[7] Thus, there is the lack of guidance specifically for pediatric patients. 
Our objective was to create a CPG for systemic antibacterial prophylaxis administration in 
pediatric cancer and HSCT patients. 
 
Methods 
General CPG Development Approach: We convened a multi-disciplinary and multi-national CPG 
panel (details in Appendices 1-3). The CPG was created using standard approaches for the development 
of evidence-based CPGs[8] with the Appraisal of Guidelines for Research & Evaluation II instrument as a 
framework[9] (details in Appendix 3).  
Panel members developed the key clinical questions (Table 1) and identified and rated the 
importance of outcomes by consensus. The Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) approach was used to determine level of evidence and to formulate 
recommendations.[10] The level of evidence was rated as high, moderate, low or very low based upon 
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certainty in treatment effects to the target population. Certainty was influenced by limitations in study 
design, and consistency, precision and directness of the data. Recommendations were either strong or 
weak. A strong recommendation was made when the benefits clearly outweighed the risks or vice versa 
and thus, patients should in general receive (or not receive) the recommended intervention as a matter of 
policy. Conversely, a weak recommendation was made when the benefits and risks of the intervention 
were closely matched or uncertain. In this setting, preferences and values should impact on intervention 
administration. In making recommendations, we considered efficacy, safety, costs and resources.  
 
Searching, Selecting and Describing the Evidence: To create this CPG, we focused on randomized 
trials because in general, they are at lower risk of bias compared to observational studies.[11] We recently 
conducted a systematic review of randomized trials of systemic antibacterial prophylaxis and described 
the efficacy and adverse effects associated with different systemic antibiotics.[12] We included both adult 
and pediatric trials in data synthesis. For this CPG, we updated the systematic review and separately 
summarized the pediatric data.  
We included outcomes that were considered critical or important to recommendation decision 
making. Resistance was examined in two ways. First, resistance was examined in studies comparing an 
antibiotic against no antibiotic controls and was defined as resistance to the intervention antibiotic among 
bacteremia isolates. These results were synthesized. Second, we also described the results of all studies 
that systematically compared acquisition or prevalence of resistant colonizing organisms at the end of the 
treatment period between randomized groups. These results were not synthesized. We used the Cochrane 
Collaboration¶s tool for assessing risk of bias in randomized trials.[13] 
 
Statistical Analysis:  
Data were synthesized using the risk ratio (RR) as the effect measure with its 95% confidence 
interval (CI). In this meta-analysis, a RR < 1 indicates that the intervention is better than control. 
Treatment effects were estimated by the Mantel-Haenszel approach and weighted by the inverse variance. 
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Analysis used a random effects model. For primary comparisons, we only synthesized outcomes when 
there were at least three studies with available data.  
We used subgroup analyses to determine whether pre-specified characteristics explained 
heterogeneity in the treatment effect. We reported stratum effects and the P value for interaction if at least 
two studies reported an outcome within each stratum.  
 
Results 
There were 114 publications included in the systematic review; the flow diagram of study 
identification and selection is described in Appendix 4. Characteristics of included trials are presented in 
Appendix 5. There were four comparisons amenable to funnel plots (data not shown). Publication bias 
was only suggested in the comparison of fluoroquinolone vs. no antibiotic for the outcome of overall 
mortality; Appendix 6 shows the plot and results of the fill and trim approach.  
Table 2 shows all evaluated interventions including the three main comparisons against no 
antibiotic, namely a fluoroquinolone, trimethoprim-sulfamethoxazole and a cephalosporin. 
Fluoroquinolone prophylaxis significantly reduced bacteremia (RR 0.56, 95% CI 0.41-0.76), fever (RR 
0.70, 95% CI 0.57-0.86) and fever and neutropenia (FN, RR 0.88, 95% CI 0.82-0.95). Fluoroquinolone 
prophylaxis was not significantly associated with more C. difficile infection, invasive fungal disease and 
musculoskeletal toxicities, while it was significantly associated with more fluoroquinolone resistance in 
bacteremia isolates (RR 3.35, 95% CI 1.12-10.03). Trimethoprim-sulfamethoxazole prophylaxis 
significantly reduced bacteremia (RR 0.59, 95% CI 0.41-0.85) and infection-related mortality (RR 0.61, 
95% CI 0.39-0.94). However, it also increased trimethoprim-sulfamethoxazole resistance in bacteremia 
isolates (RR 2.91, 95% CI 1.65-5.12). Cephalosporin prophylaxis significantly reduced bacteremia (RR 
0.30, 95% CI 0.16-0.58). Table 2 also shows that rifampin and fluoroquinolone co-administration 
significantly reduced bacteremia compared to fluoroquinolone alone (RR 0.36, 95% CI 0.17-0.77). 
Appendix 7 shows stratified analyses for a fluoroquinolone, trimethoprim-sulfamethoxazole and a 
cephalosporin vs. no antibiotic for the outcomes of bacteremia and infection-related mortality. In general, 
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evaluated factors did not explain heterogeneity in the prophylaxis effect and differences were not 
observed based upon treatment (chemotherapy, HSCT or both), participant age or risk of bacteremia in 
the control group. An exception was a marginally statistically significant interaction (P=0.04) for the 
comparison of cephalosporin vs. no antibiotic for the outcome of bacteremia when stratified by the risk of 
bacteremia in the control group.  
Table 3 shows the details of the 13 pediatric studies stratified by the comparison group. Only 
three studies were conducted in the last 15 years; all compared a fluoroquinolone vs. no antibiotic. The 
largest and most recent study included 624 patients and stratified the analysis by (a) acute myeloid 
leukemia (AML) and relapsed acute lymphoblastic leukemia (ALL), and (b) myeloablative autologous 
and allogeneic HSCT.[14] All pediatric studies of trimethoprim-sulfamethoxazole vs. no antibiotic were 
published in 1987 or earlier. 
Appendix 8 summarizes the studies that evaluated resistance in colonizing organisms at the 
completion of the study period. Among three fluoroquinolone vs. no antibiotic studies, the largest was the 
pediatric study that compared levofloxacin vs. no antibiotic.[14] This study evaluated development of 
resistance to levofloxacin, cefepime, imipenem and penicillin among a priori defined stool commensals 
and did not show a difference between randomized groups. The other two studies also showed no 
difference in resistance to ciprofloxacin[15] or norfloxacin[16] associated with fluoroquinolone 
administration. In contrast, the two trimethoprim-sulfamethoxazole vs. no antibiotic studies both 
suggested more resistant colonizing organisms in the intervention group.  
 Table 1 presents health questions, recommendations, strength of recommendation, level of 
evidence and remarks. Explanations are outlined below. Table 4 shows identified research gaps.  
 
Recommendation 1: Consider systemic antibacterial prophylaxis administration in children with AML 
and relapsed ALL receiving intensive chemotherapy expected to result in severe neutropenia (absolute 
neutrophil count < 500/uL) for at least seven days 
Weak recommendation, high quality evidence 
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Explanation: The panel deliberated the overall analyses, direct pediatric data and resistance information 
in formulating this recommendation. Direct data for pediatric patients with AML and relapsed ALL were 
available in the trial that compared levofloxacin vs. no antibiotic where the risk of bacteremia in the 
control group was 43.4%.[14] Levofloxacin prophylaxis significantly reduced bacteremia in this group 
(RR 0.50, 95% CI 0.32-0.78). Prophylaxis also significantly reduced C. difficile positive tests, and 
exposure to broad-spectrum antibiotics including aminoglycosides, third and fourth generation 
cephalosporins and antibiotics used as empiric therapy for FN among all patients (Table 3). The panel 
agreed that absolute reductions in bacteremia and FN were meaningful. Effects were consistent across 
analyses and populations, increasing quality of evidence. Further, the panel deliberated the trade-off of 
greater exposure to prophylactic antibiotics against decreasing exposure to other broad-spectrum 
antibiotics. These considerations led to a recommendation for systemic antibacterial prophylaxis in this 
population. 
However, the panel had major reservations about making a strong recommendation for systemic 
antibacterial prophylaxis. First was the clear signal of increased antibiotic resistance in bacteremia 
isolates associated with prophylaxis (Table 2). The panel was concerned that widespread adoption of 
prophylaxis could increase resistance to an extent that would preclude utilization of that antibiotic either 
for prophylaxis or treatment.[17, 18] Second, the panel highlighted that the evidence was obtained from 
studies in which selected patients (those randomized to the intervention group) were administered 
prophylaxis over a finite period of the clinical trial. The impacts of a universal prophylaxis strategy over 
multiple treatment periods at both the patient and institutional level are uncertain.[17] Third, the panel 
discussed the potential for emergence of cross-resistance beyond the administered prophylactic agent. 
Understanding local resistance epidemiology is critical to the decision of whether to implement 
prophylaxis. Finally, the synthesis failed to show that systemic antibiotic prophylaxis reduced overall 
mortality.   
The panel discussed the possibility of alternative approaches to antibacterial prophylaxis such as 
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optimizing management of bacteremia/sepsis. However, these approaches were not thought to be 
mutually exclusive as prevention of bacteremia and improving the management of bacteremia/sepsis are 
both desirable. It is also worth noting that in recent periods, mortality due to bacteremia in pediatric high-
risk populations is very rare and no deaths were reported in the large pediatric levofloxacin prophylaxis 
trial.[14]  
 
Recommendation 2: We suggest that systemic antibacterial prophylaxis not be used routinely for 
children receiving induction chemotherapy for newly diagnosed ALL 
Weak recommendation, low quality evidence 
 
Explanation: In terms of studies conducted within the last 15 years, only two trials included children 
undergoing induction therapy for ALL. One study comparing ciprofloxacin vs. placebo was conducted in 
Thailand;[19] prevalence of bacteremia in the control group was 2%. The second study was conducted in 
Indonesia and also compared ciprofloxacin vs. placebo.[20] At baseline, 37/110 were undernourished and 
abandonment during induction occurred in 10/110. The panel believed that neither of these studies were 
applicable to the setting of induction ALL in high income countries, where the risk of bacteremia 
associated with contemporary induction ALL regimens is typically greater than 10%.[21-23]  
 The panel recognized that a recommendation for administration of systemic antibacterial 
prophylaxis would have a large impact since ALL is the most common pediatric cancer diagnosis. The 
weak recommendation against routine prophylaxis was based upon the lower risk of bacteremia in the 
absence of prophylaxis (when compared to children with AML and relapsed ALL),[24] the uncertain 
benefit in this specific population and the more certain impact on resistance in bacteremia isolates. 
However, the panel also recognized heterogeneity in the risk of FN and bacteremia based upon treatment 
protocol and patient-related factors such as Down syndrome. Further data are required to identify sub-
groups of pediatric ALL patients who might particularly benefit from prophylaxis and to describe the 
effectiveness of prophylaxis in these groups. The effectiveness of prophylaxis is even more uncertain 
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during other phases of intensive ALL treatment outside of induction. Consideration could be given to 
extending this recommendation to blocks of intensive ALL chemotherapy outside of induction associated 
with prolonged severe neutropenia. 
 
Recommendation 3: Do not use systemic antibacterial prophylaxis for children whose therapy is not 
expected to result in severe neutropenia (absolute neutrophil count < 500/uL) for at least seven days 
Strong recommendation, moderate quality evidence 
 
Explanation: The relative effect of prophylaxis to reduce bacteremia did not differ based upon control 
group bacteremia risk (Appendix 7). However, the panel noted that the absolute risk reduction becomes 
clinically unimportant when the risk of bacteremia decreases sufficiently. Thus, for patients whose 
therapy is not expected to result in prolonged severe neutropenia, the panel made a strong 
recommendation against systemic antibacterial prophylaxis because patients would be exposed to adverse 
effects of prophylaxis without realizing clinically important benefits.  
 
Recommendation 4:  We suggest that systemic antibacterial prophylaxis not be used routinely for 
children undergoing autologous HSCT 
Weak recommendation, moderate quality of evidence 
 
Explanation: The rationale for this weak recommendation against routine use of antibacterial prophylaxis 
is similar to that supporting Recommendations 2 and 3.  That is, a smaller clinical benefit in comparison 
to children with AML and relapsed ALL related to the lower risk of bacteremia in the absence of 
prophylaxis, and the same anticipated downsides, including impact on resistance. The risk of bacteremia 
was derived from the recent pediatric trial[14] (Table 3) that showed a control group risk of 11.5% among 
autologous HSCT recipients compared to 43.4% among the AML and relapsed ALL group. The lack of 
interaction observed by treatment group (chemotherapy, HSCT or both) (Appendix 7) and the direct 
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evidence from the recent pediatric trial that included autologous HSCT patients[14] (Table 3) support 
similar relative effects of prophylaxis on infection outcomes in this population. However, because the 
baseline risk of bacteremia is lower in HSCT patients compared to AML and relapsed ALL patients, the 
absolute risk reduction is consequently smaller. The panel concluded that this smaller clinical benefit was 
outweighed by the impact of prophylaxis on resistance. 
There was debate about factors in autologous HSCT patients that could change the balance of 
risks and benefits. The shorter duration of neutropenia in autologous HSCT with briefer exposure to 
prophylaxis may diminish impact on resistance. However, use of tandem autologous HSCTs and resultant 
multiple cycles of prophylaxis could increase impact on resistance. The panel also noted that autologous 
HSCT is often the final intensive course of treatment and that this sequence could reduce the impact of 
resistance at the individual level although would not alter impact at the institutional level. While the panel 
made a weak recommendation against prophylaxis, institutions or providers may opt for prophylaxis if the 
reduction in bacteremia risk enables transition to outpatient therapy.  
 
Recommendation 5: We suggest that systemic antibacterial prophylaxis not be used routinely for 
children undergoing allogeneic HSCT 
Weak recommendation, moderate quality of evidence 
 
Explanation: The panel acknowledged that the granularity of available data did not allow a different 
recommendation for allogeneic compared to autologous HSCT recipients. Thus, the evidence base that 
underlies this recommendation is very similar to that made for autologous HSCT. Further, as these 
patients are routinely managed in hospital during the high-risk period, there is opportunity for very early 
empiric antibiotic administration and supportive care to reduce complications of bacteremia and severe 
sepsis. The panel noted that allogeneic HSCT recipients often have preceding conditions that could be 
associated with prophylaxis (for example, AML or relapsed ALL), have prolonged neutropenia during the 
HSCT process, and are at risk for graft-versus-host disease and subsequent intensive immunosuppressive 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/c
id
/c
iz
1
0
8
2
/5
6
1
1
0
8
7
 b
y
 L
e
e
d
s
 G
e
n
e
ra
l In
firm
a
ry
 u
s
e
r o
n
 1
0
 N
o
v
e
m
b
e
r 2
0
1
9
 13 
 
therapies, which could influence the effectiveness and adverse effects associated with prophylaxis.   
  
Recommendation 6: Levofloxacin is the preferred agent if antibacterial prophylaxis is planned  
Strong recommendation, moderate quality evidence 
 
Explanation: If used, prophylaxis should be directed at pathogens that are responsible for severe or 
difficult-to-treat infections. The strong recommendation to use levofloxacin if antibacterial prophylaxis is 
planned was based upon recent trials, direct data and the microbiological spectrum of activity. Although 
fluoroquinolones, trimethoprim-sulfamethoxazole and cephalosporins were all effective at reducing 
bacteremia, recent trials focused on fluoroquinolones. Trimethoprim-sulfamethoxazole was not 
recommended because those studies were at higher risk of bias (Appendix 7), potential for increased 
resistance in colonizing organisms (Appendix 8) and risk for drug-induced myelosuppression[25]. 
Levofloxacin in particular was preferred related to the recent large pediatric trial showing benefits[14] 
and broad-spectrum activity against important organisms in pediatric high-risk populations. 
The panel noted that levofloxacin or pediatric-friendly levofloxacin dosage forms may not be 
available in all countries. Availability of oral suspension will impact on feasibility of levofloxacin 
administration in young children treated as outpatients.  If levofloxacin is not able to be used, 
ciprofloxacin is an alternative although reduced activity relative to levofloxacin against Gram positive 
bacteria, including viridans group streptococci, may reduce the benefits of prophylaxis. Understanding 
local resistance epidemiology is critical to the decision of whether to implement fluoroquinolone 
prophylaxis.  
Although the data supported administration of a fluoroquinolone if systematic antibacterial 
prophylaxis is planned, the panel was concerned about reported adverse effects associated with these 
agents and levofloxacin in particular.[6, 26]  Patients and families should be informed about potential 
short and long-term fluoroquinolone-related adverse effects prior to administration and this information 
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/c
id
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/c
id
/c
iz
1
0
8
2
/5
6
1
1
0
8
7
 b
y
 L
e
e
d
s
 G
e
n
e
ra
l In
firm
a
ry
 u
s
e
r o
n
 1
0
 N
o
v
e
m
b
e
r 2
0
1
9
 14 
 
may lead to some families choosing against prophylaxis. If fluoroquinolones are not available or cannot 
be used, providing no systemic antibacterial prophylaxis is an important option to consider. 
 
Recommendation 7: If antibacterial prophylaxis is planned, we suggest that administration be restricted 
to the expected period of severe neutropenia (absolute neutrophil count < 500/uL)  
Weak recommendation, low quality evidence 
 
Explanation: There are no randomized trials to support different approaches to initiation and 
discontinuation of systemic antibacterial prophylaxis in this patient population. Thus, this is a weak 
recommendation based on low quality evidence. This recommendation reflects the available evidence and 
WKHSDQHO¶VGHVLUHWRPLQLPL]HGXUDWLRQRISURSK\OD[LVDGPLQLVWUDWLRQ 
 
Discussion 
In this CPG, we present recommendations for the administration of systemic antibacterial 
prophylaxis in pediatric cancer and HSCT patients. Several issues were repeatedly emphasized during 
panel discussions. First was the weighing of short-term benefits in reducing bacteremia and FN balanced 
against the more long-term potential consequences of increasing resistance rates in patients and within 
institutions. If prophylaxis is implemented, institutions should closely monitor resistance rates over time. 
Second was the acknowledgement that the trials, while critical to making recommendations, do not reflect 
consequences of a universal prophylaxis strategy either related to effectiveness or risks of prophylaxis. 
Third, although the panel recommended, based upon available trials, a fluoroquinolone as the agent for 
prophylaxis, concern was raised about the adverse effect profile. Patients and families will need to be 
informed about these risks, and these outcomes require further study in centers where prophylaxis is 
instituted.  
A limitation of the evidence base is that the number of pediatric trials precluded restricting the 
synthesis to children. In addition, trials were not conducted in the era of increasing use of immunotherapy 
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and more data in this setting are required. As with all CPGs, establishing implementation processes 
including local adaptation are important steps. Institutions will also need to decide what threshold of 
antibacterial resistance would mandate a change in policy regarding systemic antibacterial prophylaxis.  
In summary, we present a CPG for systemic antibacterial prophylaxis administration in pediatric 
cancer and HSCT patients. Future research should evaluate the long-term effectiveness and adverse 
effects of prophylaxis.   
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Table 1: Summary of Recommendations for Systemic Antibacterial Prophylaxis in Children with 
Cancer and Pediatric Hematopoietic Stem Cell Transplant Recipients   
Health Questions and Recommendations 
Strength of 
Recommendation 
and Level of 
Evidence 
Which pediatric patients with cancer and HSCT recipients (if any) should routinely receive systemic 
antibacterial prophylaxis?   
1. Consider systemic antibacterial prophylaxis administration in children with AML 
and relapsed ALL receiving intensive chemotherapy expected to result in severe 
neutropenia (absolute neutrophil count < 500/uL) for at least seven days 
 
Remarks: This is a weak recommendation because the benefits of prophylaxis were 
closely balanced against its known and potential impacts on resistance. The panel valued 
what is known about efficacy and resistance outcomes of prophylaxis administered 
within the finite time frame of a clinical trial among enrolled participants, but also 
considered the less certain impacts of a universal prophylaxis strategy at both the patient 
and institutional level. Limiting prophylaxis to patient populations at highest risk of fever 
and neutropenia, bacteremia and infection-related mortality could limit antibiotic 
utilization to those most likely to benefit from prophylaxis. Careful discussion with 
patients and families about the potential risks and benefits of prophylaxis is important. 
Understanding local resistance epidemiology is critical to the decision of whether to 
implement prophylaxis.  
Weak 
recommendation 
High quality 
evidence 
2. We suggest that systemic antibacterial prophylaxis not be used routinely for children 
receiving induction chemotherapy for newly diagnosed ALL 
 
Remarks: The panel acknowledged the paucity of direct contemporary randomized data 
applicable to children living in high income countries. A recommendation to provide 
universal systemic prophylaxis to this group could have a substantial impact on 
institutions given that ALL is the most common cancer diagnosis in children. There is 
great variability in duration of neutropenia and risk of bacteremia based upon treatment 
protocol and patient-level characteristics. Further data are required to identify sub-groups 
of pediatric ALL patients who might particularly benefit from prophylaxis. 
Weak 
recommendation 
Low quality 
evidence 
3. Do not use systemic antibacterial prophylaxis for children whose therapy is not 
expected to result in severe neutropenia (absolute neutrophil count < 500/uL) for at 
least seven days 
 
Remarks: This strong recommendation was based upon reduced chance of benefit 
combined with continued risk of harm associated with systemic antibacterial 
prophylaxis. 
Strong 
recommendation 
Moderate quality 
evidence 
4. We suggest that systemic antibacterial prophylaxis not be used routinely for children 
undergoing autologous HSCT 
 
Remarks: This weak recommendation against routine use of antibacterial prophylaxis in 
autologous HSCT recipients acknowledged the risk reduction of bacteremia among this 
cohort. However, the panel believed that the lower baseline risk of bacteremia resulted in 
the impact on resistance (known and potential) outweighing the benefits. The moderate 
quality of evidence reflected the lack of granular data specifically in autologous HSCT 
recipients rather than HSCT patients as a group. 
Weak 
recommendation 
Moderate quality 
evidence 
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5. We suggest that systemic antibacterial prophylaxis not be used routinely for children 
undergoing allogeneic HSCT 
 
Remarks: The panel acknowledged that the granularity of available data did not allow a 
different recommendation for allogeneic compared to autologous HSCT recipients. 
However, the panel noted that allogeneic HSCT recipients often have preceding 
conditions that could be associated with prophylaxis (for example, AML or relapsed 
ALL) and have prolonged neutropenia during the HSCT process, which could influence 
the effectiveness and adverse effects associated with prophylaxis.   
Weak 
recommendation 
Moderate quality 
evidence 
Which agents should be used for systemic antibacterial prophylaxis in children with cancer and HSCT 
recipients? 
6. Levofloxacin is the preferred agent if systemic antibacterial prophylaxis is planned  
 
Remarks: The strong recommendation to use levofloxacin is related to direct 
contemporary data in children and its microbiological spectrum of activity. If 
levofloxacin is not available or not able to be used, ciprofloxacin is an alternative 
although lack of activity against Gram positive bacteria including viridans group 
streptococci may reduce the benefits of prophylaxis. Patients and families should be 
informed about potential short and long-term fluoroquinolone-related adverse effects. 
Understanding local resistance epidemiology is critical to the decision of whether to 
implement fluoroquinolone prophylaxis. If fluoroquinolones are not available or cannot 
be used, providing no systemic antibacterial prophylaxis is an important option to 
consider.  
Strong 
recommendation 
Moderate quality 
evidence 
When should systemic antibacterial prophylaxis be started and stopped?  
7. If systemic antibacterial prophylaxis is planned, we suggest that administration be 
restricted to the expected period of severe neutropenia (absolute neutrophil count < 
500/uL)  
 
Remarks: This is a weak recommendation based on low quality evidence because there 
are no trials that compared different start and stop criteria. In general, trials administered 
prophylaxis during severe neutropenia and thus, this recommendation reflects the 
available evidence and the SDQHO¶VGHVLUHWRPLQLPL]Hduration of prophylaxis 
administration. 
Weak 
recommendation 
Low quality 
evidence 
 
Abbreviations: AML ± acute myeloid leukemia; ALL ± acute lymphoblastic leukemia; HSCT ± hematopoietic 
stem cell transplantation 
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Table 2: Synthesized Outcomes of All Systemic Antibacterial Prophylaxis Comparisons (Includes 
Pediatric and Adult Trials) 
 
Comparison and Outcomes Number Studies RR*** 95% CI 
I2 
(%) P 
Fluoroquinolone vs. No Antibiotic**     
Bacteremia 14 0.56 0.41 to 0.76 58 0.0002 
Fever 9 0.70 0.57 to 0.86 71 0.0008 
Neutropenic fever 8 0.88 0.82 to 0.95 0 0.0008 
Infection-related mortality 16* 0.72 0.45 to 1.16 0 0.17 
Overall mortality 15* 0.86 0.62 to 1.17 24 0.34 
C. difficile infection 3 0.62 0.31 to 1.24 0 0.17 
Invasive fungal disease 6 1.25 0.75 to 2.08 0 0.39 
Musculoskeletal adverse effects 3 0.66 0.39 to 1.13 0 0.13 
Antibiotic resistance#  4 3.35 1.12 to 10.03 64 0.03 
Fluoroquinolone vs. Non-absorbable Antibiotic 
Fever 3 0.98 0.91 to 1.05 0 0.50 
Infection-related mortality 3 0.43 0.18 to 1.05 0 0.06 
Trimethoprim-sulfamethoxazole vs. No Antibiotic** 
Bacteremia 7 0.59 0.41 to 0.85 0 0.005 
Fever 5 0.77 0.56 to 1.07 91 0.11 
Infection-related mortality 13 0.61 0.39 to 0.94 0 0.03 
Overall mortality 5 0.61 0.28 to 1.33 32 0.21 
Invasive fungal disease 7 1.19 0.43 to 3.27 27 0.74 
Antibiotic resistance#  5 2.91 1.65 to 5.12 0 0.0002 
Cephalosporin vs. No Antibiotic** 
Bacteremia 4 0.30 0.16 to 0.58 42 0.0004 
Fever 4 0.83 0.71 to 0.98 65 0.03 
Infection-related mortality 4* 1.03 0.27 to 3.95 0 0.96 
Overall mortality 3* NSP    
Antibiotic resistance# 3* NSP    
Parenteral Glycopeptide vs. No Antibiotic** 
Bacteremia 3 0.45 0.08 to 2.66 84 0.38 
Infection-related mortality 3 1.13 0.30 to 4.23 10 0.85 
Fluoroquinolone vs. Trimethoprim-sulfamethoxazole 
Bacteremia 7 0.86 0.48 to 1.54 66 0.60 
Fever 3 0.65 0.31 to 1.37 89 0.26 
Infection-related mortality 6 1.10 0.50 to 2.39 0 0.82 
Invasive fungal disease 6 0.78 0.35 to 1.75 0 0.55 
Rifampin and Fluoroquinolone vs. Fluoroquinolone    
Bacteremia 3 0.36 0.17 to 0.77 0 0.008 
Infection-related mortality 3* NSP    
Overall mortality 3* NSP    
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Abbreviations: RR- risk ratio; CI ± confidence interval; NSP ± no synthesis possible 
* One or more studies had zero events in both arms 
** No antibiotic includes no antibiotic prophylaxis and placebo control groups 
*** RR < 1 favors intervention 
# Resistance was examined in studies comparing an antibiotic against no antibiotic controls and was 
defined as resistance to the intervention antibiotic among bacteremia isolates 
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Table 3: Details of Exclusively Pediatric Studies (N=13) 
Author Year Pub Study Characteristics Findings 
Fluoroquinolone vs. No Antibiotic 
Alexander[14] 2018 Comparison: Levofloxacin vs. no antibiotic 
Population: AML, relapsed ALL and HSCT 
Number of patients: 624 
Age range: 3-16 
Country: US and Canada  
Duration of antibiotic prophylaxis: (1) Patients with acute 
leukemia: Two consecutive cycles of chemotherapy starting Day 1 or 
3; (2) HSCT recipients: One transplant procedure starting day -2 
from stem cell infusion. Prophylaxis continued until: ANC >200/uL 
after nadir, day 60 or initiation of next chemotherapy cycle   
Bacteremia frequency in control:  
AML: 25/63 (40%) 
Relapsed ALL: 18/36 (50%) 
Autologous HSCT: 9/78 (12%) 
Allogeneic HSCT: 27/130 (21%) 
Systematic surveillance of colonizing organisms tested for 
resistance: Yes 
Other: Primary analysis stratified by acute leukemia vs. HSCT 
Bacteremia: Prophylaxis reduced bacteremia among 195 
leukemia patients (RD 21.6%, 95% CI 8.8% to 34.4%) but 
not among 418 HSCT recipients (RD 6.3%, 95% CI 0.3% 
to 13.0%). 
FN: In both groups combined, prophylaxis reduced FN 
(RD 10.8%, 95% CI 4.2% to 17.5%). 
Mortality: No deaths were attributed to bacterial infection. 
CDI and IFD: Prophylaxis did not increase Clostridium 
difficile associated diarrhea (RD 2.9%, 95% CI -0.1% to 
5.9%) or IFD (RD -1.0%, 95% CI -3.4% to 1.5%).  
Resistance: Qualitatively, higher rate of resistance in 
bacteremia isolates in prophylaxis compared to control 
group. Significantly less exposure to aminoglycosides, 
third or fourth generation cephalosporin and antibiotics 
commonly used to treat FN in prophylaxis group. 
Laoprasopwattana[19] 2013 Comparison: Ciprofloxacin vs. placebo  
Population: Lymphoma and ALL undergoing induction or 
consolidation 
Number of patients: 95 
Age range: 0.25-18 
Country: Thailand  
Duration of antibiotic prophylaxis: Beginning within 5 days after 
starting chemotherapy and was discontinued when ANC of 1,000/uL 
after 2 weeks of chemotherapy. Median duration of prophylaxis was 
18 days in ciprofloxacin group and 10 days in placebo group 
Bacteremia frequency in control: 1/50 (2%) 
Systematic surveillance of colonizing organisms tested for 
resistance: Patient level data not reported 
Bacteremia: In the prophylaxis group, 2/45 developed 
bacteremia vs. 1/50 receiving placebo. 
FN and Fever: In those who developed neutropenia, 
prophylaxis reduced the occurrence of fever (RD -23.0%, 
95% CI -45.0% to -9.0%). In patients with ALL, 
prophylaxis reduced the occurrence of fever in those 
undergoing induction (RD -23.7 95% CI -45.6 to -1.8), but 
not in consolidation (RD 9.8, 95% CI -17.8 to 37.5). 
CDI and IFD: Not reported. 
Mortality: Not reported.  
Resistance: In all 3 cases of bacteremia, the causative 
organism was susceptible to ciprofloxacin.  
Widjjanto[20] 2013 Comparison: Ciprofloxacin vs. placebo 
Population: Induction ALL 
Number of patients: 110 
Age range: 1-14 
Country: Indonesia 
Duration of antibiotic prophylaxis: From start of chemotherapy 
until completion of induction treatment 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Other: At baseline, 37/110 were under-nourished. Abandonment as 
a reason for induction failure: 10/110 
Bacteremia: Not reported.  
Fever: In the prophylaxis group, 29/58 had at least one 
fever compared to 17/52 in the placebo group (P=0.07). 
Mortality: In the prophylaxis group, 11/58 died compared 
to 3/52 in the placebo group (P=0.05). 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: Clinical sepsis occurred in 29/58 patients receiving 
prophylaxis and in 20/52 patients receiving placebo 
(P=0.22).  
Trimethoprim-sulfamethoxazole vs. No Antibiotic 
Van Eys[27] 1987 Comparison: TMP-SMX vs. no antibiotic 
Population: Newly diagnosed ALL  
Number of patients: 126 
Age range: Not reported 
Country: US 
Duration of antibiotic prophylaxis: Starting week 5 of therapy and 
continuing for 3 years or until relapse 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Bacteremia: Not reported. 
FN and Fever: Not reported. 
Mortality: One infectious death occurred in each group. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: No effect of prophylaxis on disease-free survival at 
3 years. 
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Author Year Pub Study Characteristics Findings 
Goorin[28] 1985 Comparison: TMP-SMX vs. placebo 
Population: Newly diagnosed ALL (induction, consolidation, early 
maintenance) 
Number of patients: 61 
Age range: 1-16 
Country: US 
Duration of antibiotic prophylaxis: Immediately after diagnosis 
and continued daily during induction, intensification and early 
maintenance phases for ~40 weeks 
Bacteremia frequency in control: Not reported 
Systematic surveillance of colonizing organisms tested for 
resistance: Only for patients in the first year of the study due to 
difficulties collecting routine stool samples 
Bacteremia: In the prophylaxis group there were fewer 
episodes of bacteremia compared to placebo (0 vs. 5). 
FN and Fever: Not reported. 
Mortality: One death occurred in the study and it was due 
to an infection in the placebo group. 
CDI and IFD: Not reported. 
Resistance: In the prophylaxis group, 5/19 patients' stool 
surveillance cultures developed Gram-negative bacilli 
resistant to TMP-SMX compared to 0/18 in the placebo 
group (P=0.05). 
Kovatch[29] 1985 Comparison: TMP-SMX vs. placebo 
Population: Induction ALL and AML; relapsed ALL and solid 
tumors 
Number of patients: 91 
Age range: 0.25 -17 
Country: US 
Duration of antibiotic prophylaxis: Started day 2 or 3 of induction 
chemotherapy. Continued in the leukemia group until remission and 
in the solid tumor group until 60 days following chemotherapy 
initiation 
Bacteremia frequency in control: Overall not reported. In the sub-
group that developed neutropenia: 
Induction leukemia: 6/26 (23%) 
Reinduction leukemia: 0/2 (0%) 
Solid tumors: 1/7 (14%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Bacteremia: Bacteremia reported for the sub-group of 
patients that developed neutropenia. In this sub-group, 1/39 
receiving prophylaxis vs. 7/35 in the placebo group 
developed bacteremia. 
Fever: In the prophylaxis group 14/43 had a febrile 
episode compared to 25/48 in the placebo group (P=0.10). 
Mortality: Two infection-related deaths occurred, both in 
the placebo group. 
CDI and IFD: No IFD occurred in either group. CDI not 
reported. 
Resistance: In the neutropenic sub-group developing 
bacteremia, the 1 bacteremia in the prophylaxis group and 
1/7 in the placebo group were resistant to TMP-SMX. 
Lange[30] 1984 Comparison: TMP-SMX and nystatin vs. no antibiotic 
Population: Newly diagnosed ALL (induction) 
Number of patients: 67 
Age range: 0.5-16 
Country: US 
Duration of antibiotic prophylaxis: Not clear 
Bacteremia frequency in control:  5/25 (20%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
 
Bacteremia: In the prophylaxis group 2/25 developed 
bacteremia vs. 5/35 in the no antibiotic group. 
Fever: Not reported. 
Mortality: There was one infection-related death in each 
group. 
CDI and IFD: One IFD occurred, in the control group. 
CDI not reported. 
Resistance: Both cases of bacteremia in the prophylaxis 
group were resistant to TMP-SMX. No information on the 
control group. 
Inoue[31] 1982 Comparison: TMP-SMX vs. placebo 
Population: Induction, maintenance and relapsed ALL and AML 
Number of patients: 102 
Age range: Not reported 
Country: Japan 
Duration of antibiotic prophylaxis: Not clear  
Systematic surveillance of colonizing organisms tested for 
resistance: Yes 
Bacteremia frequency in control: Not reported 
Bacteremia: Narratively reported bacterial sepsis occurred 
less frequently in the group receiving prophylaxis.   
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
 
Fluoroquinolone vs. Trimethoprim-sulfamethoxazole  
Cruciani[32] 1989 Comparison: Norfloxacin vs. TMP-SMX 
Population ALL, AML, lymphoma, neuroblastoma 
Number of patients: 44 
Age range: Not reported 
Country: Italy 
Duration of antibiotic prophylaxis: Children receiving induction 
remission chemotherapy. Discontinued when neutrophil count 
exceeded 1000/uL 
Bacteremia frequency in control: Not applicable, as prophylaxis 
control group 
Systematic surveillance of colonizing organisms tested for 
resistance: Yes 
Bacteremia: In the norfloxacin group, 4/21 developed 
bacteremia vs. 4/23 in the TMP-SMX group. 
Fever: In norfloxacin group, 9/21 had at least one fever vs. 
20/23 in the TMP-SMX group. 
Mortality: There was one infection-related death in each 
group. 
CDI and IFD: Not reported. 
Resistance: Did not report number of patients with newly 
developed resistance. 
Others    
Castagnola[33] 2003 Comparison: Amoxicillin/clavulanate vs. placebo 
Population: Leukemia, lymphoma or solid tumor 
Number of patients: 167 
Age range: 0-18 
Bacteremia: In the prophylaxis group, 3/84 developed 
bacteremia vs. 5/83 in the placebo group. 
Fever:  
Mortality: One death occurred in the study and it was due 
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Author Year Pub Study Characteristics Findings 
Country: Italy 
Duration of antibiotic prophylaxis: Started when neutropenia 
developed during chemotherapy. Continued until bone marrow 
recovery (generally 500-1000/uL) 
Bacteremia frequency in control: Not applicable, as prophylaxis 
control group 
Bacteremia frequency in control: 5/83 (6%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
to an infection in the prophylaxis group. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Avril[34] 1994 Comparison: Ceftazidime and teicoplanin vs. no antibiotic 
Population: Autologous HSCT  
Number of patients: 60 
Age range: 2-16 
Country: France 
Duration of antibiotic prophylaxis: Started 3-4 days before the 
onset of aplasia and continued until aplasia resolved. 
Bacteremia frequency in control: 7/29 (24%) 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Bacteremia: In the prophylaxis group, 2/30 developed 
bacteremia vs. 7/29 in the group receiving no prophylaxis. 
Fever: In the prophylaxis group, 28/30 had fever vs. 29/29 
in the group receiving no prophylaxis. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Arico[35] 1992 Comparison: TMP-SMX daily vs. TMP-SMX three days a week 
Population: Maintenance ALL 
Number of patients: 77 
Age range: Not reported 
Country: Italy 
Duration of antibiotic prophylaxis: Not clear 
Bacteremia frequency in control: Not applicable, as prophylaxis 
control group 
Systematic surveillance of colonizing organisms tested for 
resistance: No 
Bacteremia: Not reported. 
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
 
Rossi[36] 1987 Comparison: TMP-SMX daily vs. TMP-SMX three days a week 
Population: Newly diagnosed and relapsed ALL or AML 
Number of patients: 97 
Age range: 0.9-15 
Country: Italy 
Duration of antibiotic prophylaxis: For the duration of 
antineoplastic treatment starting from the first day of induction. 
Median duration of prophylaxis was 144 days in the daily group and 
110 days in the control group 
Bacteremia frequency in control: Not applicable, as prophylaxis 
control group. 
Systematic surveillance of colonizing organisms tested for 
resistance: No  
Bacteremia: Two episodes of bacteremia in each group. 
Fever: Not reported. 
Mortality: Not reported. 
CDI and IFD: Not reported. 
Resistance: Not reported. 
Other: The number of severe infections and side effects 
were similar between the groups. 
 
Abbreviations: Pub ± published; AML ± acute myeloid leukemia; ALL ± acute lymphoblastic leukemia; US ± United States; NR ± not reported; 
TMP-SMX ± trimethoprim-sulfamethoxazole; HSCT ± hematopoietic stem cell transplantation; RD ± risk difference; CI ± confidence interval; 
FN ± fever and neutropenia; CDI ± Clostridium difficile infection; IFD ± invasive fungal disease; ANC ± absolute neutrophil count 
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Table 4: Key Knowledge Gaps Related to Systemic Antibacterial Prophylaxis among Children with 
Cancer and Pediatric Hematopoietic Stem Cell Transplantation Recipients   
 
To determine whether the effectiveness of systemic antibacterial prophylaxis changes when 
administered over a prolonged period of time within individuals and within institutions 
To determine the consequences of a universal systemic antibacterial prophylaxis strategy within 
individuals (both those receiving and not receiving prophylaxis) and within institutions 
To describe sub-groups of patients undergoing induction chemotherapy for acute lymphoblastic 
leukemia at higher risk of bacteremia and infection-related mortality 
To determine the risks and benefits of systemic antibacterial prophylaxis in children undergoing 
induction chemotherapy for acute lymphoblastic leukemia 
To determine the risks and benefits of systemic antibacterial prophylaxis for children with acute 
lymphoblastic leukemia receiving intensive chemotherapy phases other than induction such as delayed 
intensification 
To identify sub-groups of patients at higher risk of bacteremia and infection-related mortality (other 
than those identified in this clinical practice guideline such as child with solid tumor receiving 
intensive chemotherapy) such that the risks and benefits of systemic antibacterial prophylaxis can be 
considered 
To determine the cost-effectiveness of antibacterial prophylaxis in different patient populations 
To compare the risks and benefits of levofloxacin and ciprofloxacin prophylaxis  
To identify facilitators of guideline-concordant care 
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